Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform recommendation. Analyst Price Forecast Suggests 965.88% Upside As of March 19 ...

As of March 19, 2025, the average one-year price target for Immunic is $13.43/share ... data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel ...

Research analysts at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The ...

On Tuesday, William Blair initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating, highlighting the potential of its relapse-remitting multiple sclerosis (RMS) therapy ...

On Tuesday, William Blair initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating, highlighting the potential of its relapse-remitting multiple sclerosis (RMS) therapy, vidofludimus ...

Finally, William Blair began coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating for the company. One investment analyst has rated the ...